Differentiate your GLP-1 drug with the right endpoint strategy
In the race for GLP-1 agonist therapies, you need to stand out. Leverage expert strategies and precise data to maximize your success.
In our on-demand webinar, learn clinical trial strategies to characterize safety and efficacy, while also generating meaningful data to differentiate your drug.
Enhance your GLP-1 trial success with expertise you can trust
We offer a robust combination of scientific prowess, advanced technologies, and a proven track record to support your development program, including:
- Unmatched expertise: Featuring dozens of peer-reviewed manuscripts focused on Type 2 diabetes and obesity drug development
- Consistent, accurate results: Leverage innovative technologies and workflows to generate precise data you can trust
- Speed and efficiency: Accelerate study setup and data analysis to enable informed decision-making
- Differentiation by design: From body composition, cardiometabolic, behavioral, and quality-of-life endpoints that strengthen your label and your commercial story
Transform your GLP-1 trial with insights from our experts.
Key webinar highlights
Comprehensive assessment
Explore advanced imaging to document therapeutic gains and mitigate risks, including shifts in visceral fat, liver fat, and lean muscle mass, for stronger regulatory evidence.
Real-world differentiation
Learn to differentiate treatments using patient-reported outcomes that showcase real-world impacts on quality of life.
Innovative solutions
Discover how digital endpoints, including Blood glucose meters (BGM) and continuous glucose monitors (CGM), strengthen GLP-1 trial safety, efficacy, and value through high-quality data.
Deliver precise endpoint data and outpace competitors
Overcome the complexities of your GLP-1 trials with our comprehensive clinical trial endpoint solutions. We help with:
- Ensuring data consistency and regulatory compliance
- Selecting and using the right digital endpoints
- Accessing trusted GLP-1 development expertise
- Speeding up market entry in a competitive space
- Differentiating beyond weight loss
Proven results across GLP-1 and next-generation metabolic trials
Our results* speak volumes:
- Supported over 250+ GLP-1 studies, including all currently FDA and EMA-approved GLP-1 agonists
- Experience supporting the next-generation GLP-1 programs, from new treatment approaches to dual and triple agonists (GLP-1/GIP, GLP-1/glucagon)
- Delivered consistent data leveraging a full range of digital endpoint solutions, characterizing drug safety, efficacy, and patient quality of life
- Supported over 1,040 diabetes and weight management clinical trial opportunities
*Accurate as of April 2026, based on FDA and EMA approvals
Healthy futures start here
Explore how innovative imaging, cardiac and patient-reported endpoint strategies can maximize your trial’s value, maintain regulatory compliance, and drive success. Don’t miss this opportunity to learn from industry experts and elevate your GLP-1 clinical trials.